RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-813
Malaria parasiteP. berghei
Genotype
DisruptedGene model (rodent): PBANKA_1318100; Gene model (P.falciparum): PF3D7_1454400; Gene product: aminopeptidase P (APP)
Transgene
Transgene not Plasmodium: A fusion of GFP (gfp-mu3) and Luciferase Firefly (LucIAV)
Promoter: Gene model: PBANKA_0915000; Gene model (P.falciparum): PF3D7_1133400; Gene product: apical membrane antigen 1
3'UTR: Gene model: PBANKA_0719300; Gene product: bifunctional dihydrofolate reductase-thymidylate synthase, putative (dhfr/ts)
Replacement locus: Gene model: PBANKA_0306000; Gene product: 6-cysteine protein (230p)
Phenotype Asexual bloodstage;
Last modified: 1 April 2024, 18:58
  *RMgm-813
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 25941254
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone P. berghei ANKA 1037m1f1mocl1 (RMgm-32)
Other information parent lineP. berghei ANKA 1037m1f1mocl1 (1037cl1; RMgm-32) is a reference ANKA mutant line which expresses GFP-luciferase under control of a schizont-specific promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 20019192).
The mutant parasite was generated by
Name PI/ResearcherJ. Lin; C.J. Janse; S.M. Khan
Name Group/DepartmentLeiden Malaria Research Group
Name InstituteLeiden University Medical Center
CityLeiden
CountryThe Netherlands
Name of the mutant parasite
RMgm numberRMgm-813
Principal name2129cl2; 2248cl1
Alternative name∆app-a; ∆app-b
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageBlood stages show a strongly reduced growth rate in mice and produce strongly reduced levels of hemozoin compared to wild type parasites.
Gametocyte/GameteNot different from wild type
Fertilization and ookineteNot different from wild type
OocystNot different from wild type
SporozoiteNot different from wild type
Liver stageNot different from wild type
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of APP and expresses the GFP-Luciferase fusion protein under control of the (schizont specific) ama-1 promoter.

Protein (function)
The metalloenzyme aminopeptidase P catalyzes the hydrolysis of amino acids from the amino termini of peptides with a prolyl residue in the second position. P. falciparum and P. berghei expresses a homolog of aminopeptidase P during its asexual intraerythrocytic cycle. P. falciparum aminopeptidase P (PfAPP) shares with mammalian cytosolic aminopeptidase P a three-domain, homodimeric organization and is most active with Mn(II) as the cofactor.
PfAPP is present in the food vacuole and cytosol of the parasite, a distribution that suggests roles in vacuolar hemoglobin catabolism and cytosolic peptide turnover. Evidence has been presented for roles for PfAPP in peptide catabolism in both the food vacuole and the cytosol.

Phenotype
Blood stages show a strongly reduced growth rate in mice and produce strongly reduced levels of hemozoin compared to wild type parasites.

In a paper published in 2024 (https://doi.org/10.1101/2023.10.24.563045) mutant parasites lacking expression of APP were analyzed during mosquito development. Mosquito development was comparable to wild type parasites).

Additional information

Figure: Generation of P. berghei mutants ∆app (RMgm-813), ∆lap (RMgm-814) and ∆dap (RMgm-815).
(primer sequences can either be found in Lin et al. (2015). J. Exp. Med. or obtained from the Leiden Malaria Research Group)
(A) Schematic representation of the gene-deletion constructs targeting the ORF of genes expressing aminopeptidase P (app), leucyl aminopeptidase (lap) and aspartyl aminopeptidase (dap) by double cross-over homologous recombination and the wt gene loci before and after disruption. The constructs contain a drug-selectable marker cassette (SM; black box) and gene target regions (hatched boxes). Primer positions (arrows) for diagnostic PCRs are shown (see Table S4 for primer sequences and expected product sizes). (B) Diagnostic PCR (left) and Southern analysis of pulsed field gel-separated chromosomes (center) confirm correct disruption of app in ∆app-a and ∆app-b. Northern analysis of blood-stage mRNA (right) confirms the absence of the app transcripts in the ∆app mutants. The following primers were used for diagnostic PCRs: 5' integration (5’ in): L7107/L4770; 3' integration (3’ in): L4771/L7108; SM (hdfhr::yfcuI): L4698/L4699; app ORF: L7109/L7110. Separated chromosomes of ∆app-a and ∆app-b were hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into the app locus on chromosome 13, the endogenous dhfr/ts on chromosome 7 and the GFP-luciferase reporter cassette in the 230p locus on chromosome 3. Northern blot was hybridized using a PCR probe recognizing the app ORF (primers L7109/L7110) and with an oligonucleotide probe L644R recognizing the large subunit rRNA (as loading control). (C) Diagnostic PCR (left) and Southern analysis of separated chromosomes (center) confirm correct disruption of lap in mutant ∆lap. Northern analysis of blood-stage mRNA (right) confirms the absence of lap transcripts in the ∆lap mutant. The following primers were used for diagnostic PCRs: 5’ in, L6967/L4770; 3’ in, L4771/L6968; SM (hdfhr::yfcu), L4698/L4699; lap ORF, L6969/L6970. Separated chromosomes were hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into lap on chromosome 13, the endogenous dhfr/ts on chromosome 7 and the GFP-luciferase reporter cassette in the 230p locus on chromosome 3. Northern blot was hybridized using a PCR probe recognizing lap ORF (primers L6969/L6970) and with an oligonucleotide probe L644R recognizing the large subunit rRNA (as loading control). (D) Diagnostic PCR (left) and Southern analysis of pulsed field gel-separated chromosomes (center) confirm correct disruption of dap in ∆dap. Northern analysis of blood-stage mRNA (right) confirms the absence of the lap transcripts in the ∆dap mutant. The following primers were used for diagnostic PCRs: 5’ in, L6975/L4770; 3’ in, L4771/L6976; SM (hdfhr::yfcu), L4698/L4699; dap ORF, L6977/L6978. Separated chromosomes were hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into dap on chromosome 8, the endogenous dhfr/ts on chromosome 7 and the GFP-luciferase reporter cassette in the 230p locus on chromosome 3. For Northern blot was hybridized using a PCR probe recognizing dap ORF (primers L6977/L6978) and with an oligonucleotide probe L644R recognizing the large subunit rRNA (as loading control). See Table S4 for primers used for generation of probes.

Other mutants


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_1318100
Gene Model P. falciparum ortholog PF3D7_1454400
Gene productaminopeptidase P
Gene product: Alternative nameAPP
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) PCR construct double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Click to view information
Click to hide information
Plasmid/construct sequence
Click to view information
Click to hide information
GAACTCGTACTCCTTGGTGACGTCGCGATATTACACATAAGGGCTGAATTGAATTAAAAA
TAAAAAATATAGGAATTACATAATATTAATATAAAACTGCTTTTATATCCATTAGGAAAT
AAAAATATTAGATACGTATATATATTCTTGGTATTTTTTGTGTTTAATAAGATCCGCCCC
CTTTATTCTCGATATTTAAAATTGCTTTTCAAGTAAATGCTAAAAATATTCCATTCATAT
ATTATTATAAAGTCATATAAACTATATATGTTTTACATATAGAAAATACCACATTTCTAT
TAGAATTTCTATTATCAATATTATATATAATATCCATGGCATACATTGTGCTCCGTTATG
TAATAAGTACATATATCTTTTCCTAAAAATATTTAATTTAAAAAAAGCAGCAATTAAATA
GTTATTATATAGGCAATATCATAATTATTATATCTTCATTATTTTTTTTTATATAACATT
TTACTAAACTTATAATTTATTCGTCCCTTAAATTCTCCCTTTCGATCTCTATTATACCTA
CTATTACATAATAGGATATATGCATTATTATTTTTTTTTCGTATAGAGAGAAATTACGCC
TTTTAGATTTAAAAAAAAGGAAAATATTTATATAGTAAAAAAGGTTTTATGTAAAATTAG
GAATATATTTTTTTTTAATTATTACAAATAATTATTTGCTATACATATTTAATTATATAT
ATGATATAATAAATATGGAAAAATAATTACGATAGAATTATAAATATATGTTTATTCAGT
ATGTTTATATATAAAATTTGAAAAAGAATAATATATATTTAAGTATATGCAAAAGGGTTT
AGTGTGGGCTATACAAAAAAGGTTTAAAAACCACATAAAATATAATTCGTATATGTATAT
AATATATGCCCATATGAGGTCGACGATGCTTGTAGATGGCCCAGCTTAATTCTTTTCGAG
CTCTTTATGCTTAAGTTTACAATTTAATATTCATACTTTAAGTATTTTTTGTAGTATCCT
AGATATTGTGCTTTAAATGCTCACCCCTCAAAGCACCAGTAATATTTTCATCCACTGAAA
TACCATTAAATTTTCAAAAAAATACTATGCATATAATGTTATACATATAAACATAAAACG
CCATGTAAATCAAAAAATATATAAAAATATGTATAAAAATAAATATGCACTAAATATAAG
CTAATTATGCATAAAAATTAAAGTGCCCTTTATTAACTAGTCGTAATTATTTATATTTCT
ATGTTATAAAAAAATCCTCATATAATAATATAATTAATATATGTAATGTTTTTTTTATTT
TATAATTTTAATATAAAATAATATGTAAATTAATTCAAAAAATAAATATAATTGTTGTGA
AACAAAAAACGTAATTTTTTCATTTGCCTTCAAAATTTAAATTTATTTTAATATTTCCTA
AAATATATATACTTTGTGTATAAATATATAAAAATATATATTTGCTTATAAATAAATAAA
AAATTTTATAAAACATAGGGGGATCCATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGT
CCCAGAACATGGGCATCGGCAAGAACGGGGACCTGCCCTGGCCACCGCTCAGGAACGAAT
TTAGATATTTCCAGAGAATGACCACAACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGA
TTATGGGTAAGAAGACCTGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAA
TTAATTTAGTTCTCAGCAGAGAACTCAAGGAACCTCCACAAGGAGCTCATTTTCTTTCCA
GAAGTCTAGATGATGCCTTAAAACTTACTGAACAACCAGAATTAGCAAATAAAGTAGACA
TGGTCTGGATAGTTGGTGGCAGTTCTGTTTATAAGGAAGCCATGAATCACCCAGGCCATC
TTAAACTATTTGTGACAAGGATCATGCAAGACTTTGAAAGTGACACGTTTTTTCCAGAAA
TTGATTTGGAGAAATATAAACTTCTGCCAGAATACCCAGGTGTTCTCTCTGATGTCCAGG
AGGAGAAAGGCATTAAGTACAAATTTGAAGTATATGAGAAGAATGATGCTAGCGGAGGAG
GTGGATCTGGTGGAGGTGGAAGTGCTAGCGTGACAGGGGGAATGGCAAGCAAGTGGGATC
AGAAGGGTATGGACATTGCCTATGAGGAGGCGGCCTTAGGTTACAAAGAGGGTGGTGTTC
CTATTGGCGGATGTCTTATCAATAACAAAGACGGAAGTGTTCTCGGTCGTGGTCACAACA
TGAGATTTCAAAAGGGATCCGCCACACTACATGGTGAGATCTCCACTTTGGAAAACTGTG
GGAGATTAGAGGGCAAAGTGTACAAAGATACCACTTTGTATACGACGCTGTCTCCATGCG
ACATGTGTACAGGTGCCATCATCATGTATGGTATTCCACGCTGTGTTGTCGGTGAGAACG
TTAATTTCAAAAGTAAGGGCGAGAAATATTTACAAACTAGAGGTCACGAGGTTGTTGTTG
TTGACGATGAGAGGTGTAAAAAGATCATGAAACAATTTATCGATGAAAGACCTCAGGATT
GGTTTGAAGATATTGGTGAGGCTTCGGAACCATTTAAGAACGTCTACTTGCTACCTCAAA
CAAACCAATTGCTGGGTTTGTACACCATCATCAGAAATAAGAATACAACTAGACCTGATT
TCATTTTCTACTCCGATAGAATCATCAGATTGTTGGTTGAAGAAGGTTTGAACCATCTAC
CTGTGCAAAAGCAAATTGTGGAAACTGACACCAACGAAAACTTCGAAGGTGTCTCATTCA
TGGGTAAAATCTGTGGTGTTTCCATTGTCAGAGCTGGTGAATCGATGGAGCAAGGATTAA
GAGACTGTTGTAGGTCTGTGCGTATCGGTAAAATTTTAATTCAAAGGGACGAGGAGACTG
CTTTACCAAAGTTATTCTACGAAAAATTACCAGAGGATATATCTGAAAGGTATGTCTTCC
TATTAGACCCAATGCTGGCCACCGGTGGTAGTGCTATCATGGCTACAGAAGTCTTGATTA
AGAGAGGTGTTAAGCCAGAGAGAATTTACTTCTTAAACCTAATCTGTAGTAAGGAAGGGA
TTGAAAAATACCATGCCGCCTTCCCAGAGGTCAGAATTGTTACTGGTGCCCTCGACAGAG
GTCTAGATGAAAACAAGTATCTAGTTCCAGGGTTGGGTGACTTTGGTGACAGATACTACT
GTGTTTAACTCGATCCCGTTTTTCTTACTTATATATTTATACCAATTGATTGTATTTATA
ACTGTAAAAATGTGTATGTTGTGTGCATATTTTTTTTTGTGCATGCACATGCATGTAAAT
AGCTAAAATTATGAACATTTTATTTTTTGTTCAGAAAAAAAAAACTTTACACACATAAAA
TGGCTAGTATGAATAGCCATATTTTATATAAATTAAATCCTATGAATTTATGACCATATT
AAAAATTTAGATATTTATGGAACATAATATGTTTGAAACAATAAGACAAAATTATTATTA
TTATTATTATTTTTACTGTTATAATTATGTTGTCTCTTCAATGATTCATAAATAGTTGGA
CTTGATTTTTAAAATGTTTATAATATGATTAGCATAGTTAAATAAAAAAAGTTGAAAAAT
TAAAAAAAAACATATAAACACAAATGATGTTTTTTCCTTCAACCTTCAATTTCGGATCCA
CTAGCCATTTATTATATGTGTGTTTTAATTCAAGTGAAATATATGTTGTGTTATTATATG
CCTGATTATATTGGTACAGAAATAAGTATAAGTTATATATATGTGGGTACTATTTTTTTT
TCCCTATTTTTTAAATTTTGGGTTTTAAATATTCTTATGTTTTTTATGATCAAAATAAGG
GATTTATATGATTGTACCGTAAAACATATAATTGCTAAAGTTATAATTCAAAATAATTTT
TTTTGCCAATCAAAATAAGAGATATATGCATTATTAAAAAAGCGCAAAGCAGCCATATAT
CCATAAAATTAGAATGTTTAATTTGGTATTTACAATCATAAGCAATATATATAAGAAAGT
ATTTAAAAAATAAATTATAAACAAATCTTTAATTCTTAATTGTGCTAATTATATATACAT
TTTATATGGTTTCTTCTTTGTCTAGTTTTGGATTTATTCAAATTGTTTTTTATTTTTTTA
TAAATTATGGGAAAATAATTAATACATGCATATATATATTAACAAAAGATGAAAAAGGGA
CAATGACTCCTTAACGCATTTATACATATTTTTTTCCATATATTTTTTTTTAAATAACTA
AAATATCAATTATATATATTTAAAAAAGCAGTAAAAATATGTAACAATTTTATAGGATGC
TAATTTTTTTGTGCAAGGAATATATACATATATAATTTTTTTTAATCTTCGAATTATTTG
AGATTCCTTTTATAAATTATGATGTATATTTATGCAAATTTATATTTTTTATTAAATGTA
TATTGTTATTATATAAAAAAATAAATGTACATAATATTATATAACTAAATTAATGCTTTG
TTTGATAATTTTACCGTTTCGCGAGCTGAGTGTCAATGACCAACCT
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationThe locus was targeted using a linear construct that was generated using a 2-step, anchor tagging PCR method (for primer details see below).

The 5’- and 3’ targeting regions of the gene were PCR amplified from genomic DNA using primer pairs 1&2 and 3&4. Primers 2 and 3 have 5’-terminal extensions homologues to the hdhfr::yfcu selectable marker cassette. Primers 1 and 4 both have a 5’-terminal overhang with an anchor-tag which serves as a primer site in the 2nd PCR reaction.

The target fragments from the first PCR reaction were annealed to either side of the selectable marker cassette by PCR with anchor-tag primers 5 and 6, resulting in the 2nd PCR product. The hdhfr::yfcu selectable marker cassette used in this reaction was digested from pL0048 using restriction enzymes XhoI and NotI. pL0048 is available from The Leiden Malaria Research Group.

See for more information on the 2-step anchor tagging PCR method, the following publications:
J.W. Lin, S.M. Khan et al. A novel 'gene insertion/marker out' (GIMO) method for transgene expression and gene complementation in rodent malaria parasites PLoS One. 2011;6(12).
T. Annoura et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates Vaccine. 2012;30(16):2662-70
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1GAACTCGTACTCCTTGGTGACGTCGCGATATTACACATAAGGGCTGAATTG
Additional information primer 1L7103; app 5’-targeting sequence, F (NruI)
Sequence Primer 2CATCTACAAGCATCGTCGACCTCATATGGGCATATATTATATACATATAC
Additional information primer 2L7104; app 5’-targeting sequence, R
Sequence Primer 3CCTTCAATTTCGGATCCACTAGCCATTTATTATATGTGTGTTTTAATTC
Additional information primer 3L7105; app 3’-targeting sequence, F
Sequence Primer 4AGGTTGGTCATTGACACTCAGCTCGCGAAACGGTAAAATTATCAAACAAAG
Additional information primer 4L7106; app 3’-targeting sequence, R (NruI)
Sequence Primer 5GAACTCGTACTCCTTGGTGACG
Additional information primer 5L4661; anchor tag primer
Sequence Primer 6AGGTTGGTCATTGACACTCAGC
Additional information primer 6L4662: anchor tag primer

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameA fusion of GFP (gfp-mu3) and Luciferase Firefly (LucIAV)
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid KspI (SacII)
Selectable marker used to select the mutant parasitegfp (FACS)
Promoter of the selectable markerama-1
Selection (positive) procedureFACS (flowsorting)
Selection (negative) procedureNo
Additional remarks genetic modificationThe GFP-Luciferase gene (1 copy) has been inserted into the 230p locus (PB000214.00.0) by double cross-over integration.
Additional remarks selection procedureThis reporter mutant expressing GFP-Luciferase does not contain a drug-selectable marker. This mutant has been selected by FACS sorting after transfection based on GFP fluorescence.
Other details transgene
Promoter
Gene Model of Parasite PBANKA_0915000
Gene Model P. falciparum ortholog PF3D7_1133400
Gene productapical membrane antigen 1
Gene product: Alternative name
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0719300
Gene productbifunctional dihydrofolate reductase-thymidylate synthase, putative
Gene product: Alternative namedhfr/ts
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0306000
Gene product6-cysteine protein
Gene product: Alternative name230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4